CAR T-cells approved by EPA for phase 2 trial

23 May 2024

An exciting milestone in our pursuit to make CAR T-cell therapy a standard of care in New Zealand, the Environmental Protection Authority NZ has approved use of chimeric antigen receptor (CAR) T-cells in our phase 2 clinical trial with BioOra.

As a trial of this kind had never been done before in New Zealand, our team has put significant time and effort into working with national regulatory bodies such as the EPA and MedSafe to navigate and establish the necessary regulatory pathways to bring CAR T-cell technology to New Zealand.

In doing so, we have opened doors for similar life-saving cell therapy trials to be undertaken here in the future - whether our own or others.

Read the EPA's media release and decision documents.